A comparative study on safety and tolerability of rasagiline versus pramipexole in early Parkinson's disease (PD): The ACTOR study

被引：0
|
作者：
Viallet, F.
Pitel, S.
Lancrenon, S.
Blin, O.
机构：
来源：
MOVEMENT DISORDERS | 2012年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
450
引用
收藏
页码：S144 / S145
页数：2
相关论文
共 50 条
  • [21] Safety and efficacy of pramipexole in early Parkinson disease - A randomized dose-ranging study
    Kieburtz, K
    Shoulson, I
    McDermott, M
    Fahn, S
    Lang, A
    Olanow, W
    Penney, J
    Wooten, GF
    Kurlan, R
    Gardiner, I
    Petzinger, G
    Brin, M
    Dillon, S
    Shannon, K
    Jaglin, JA
    Trosch, R
    Mistura, K
    Harrison, M
    RostRuffner, E
    Tanner, C
    Singer, C
    Weiner, W
    Sheldon, C
    Grimes, JD
    Gray, P
    Hurtig, H
    Hauser, R
    Gauger, L
    Rajput, A
    Rudnitzky, R
    Dobson, J
    Panisset, M
    Gauthier, S
    Amyot, D
    Perlmutter, J
    Hubble, J
    Barter, R
    Suchowersky, O
    Lew, M
    Welsh, M
    Marek, K
    Fussell, B
    Sethi, K
    Ligon, K
    Rao, J
    Rudolph, A
    Casaceli, C
    Day, D
    Johnston, K
    Baker, D
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 278 (02): : 125 - 130
  • [22] Early Versus Late Levodopa Administration In Parkinson's Disease: Comparative Study
    Akid, A.
    Kacem, I.
    Guedi, A.
    Abida, Y.
    Mrabet, S.
    Souissi, A.
    Gharbi, A.
    Nasri, A.
    Gouider, R.
    MOVEMENT DISORDERS, 2023, 38 : S98 - S98
  • [23] Safety of rasagiline for the treatment of Parkinson's disease
    Perez-Lloret, Santiago
    Rascol, Olivier
    EXPERT OPINION ON DRUG SAFETY, 2011, 10 (04) : 633 - 643
  • [24] Sustained efficacy and tolerability of pramipexole extended-release in early Parkinson's disease
    Poewe, W.
    Barone, P.
    Hauser, R.
    Mizuno, Y.
    Rascol, O.
    Harjula, J.
    Sohr, M.
    Salin, L.
    Shapira, A. H. V.
    MOVEMENT DISORDERS, 2010, 25 (07) : S306 - S306
  • [25] Efficacy of rasagiline monotherapy for Parkinson's disease (PD)
    Prisco, UL
    Fitzer-Attas, C
    Oren, S
    ANNALS OF NEUROLOGY, 2005, 58 : S55 - S55
  • [26] A controlled trial of rasagiline in early Parkinson disease - The TEMPO study
    Siderowf, A
    Stern, M
    Shoulson, I
    Kieburtz, K
    Oakes, D
    Day, D
    Shinaman, A
    Plumb, S
    Fahn, S
    Blindauer, K
    Lew, M
    Hurtig, H
    Lloyd, M
    Hauser, R
    Gauger, L
    Golbe, L
    Wojcieszek, J
    Belden, J
    Feigin, A
    Klimek, ML
    Shannon, B
    Ondo, W
    Hunter, C
    Calabrese, V
    Allen, C
    Berry, D
    Gardiner, I
    Miyasaki, J
    Del Rizzo, L
    Mendis, T
    Mendis, N
    Gray, P
    Hubble, J
    Betcher, K
    Pahwa, R
    Molho, E
    Brown, D
    Shulman, L
    Rajput, A
    Ewanishin, M
    Stacy, M
    Williamson, K
    Bertoni, J
    Peterson, C
    Tuite, P
    Ebbitt, B
    Shannon, K
    Jaglin, J
    Tanner, C
    Marek, K
    ARCHIVES OF NEUROLOGY, 2002, 59 (12) : 1937 - 1943
  • [27] A comparative randomised study of rasagiline versus placebo or entacapone as adjunct to levodopa in Parkinson's disease patients with motor fluctuations (the LARGO Study)
    Rascol, O
    MOVEMENT DISORDERS, 2004, 19 : S200 - S201
  • [28] A "Real World" View of the Tolerability of Rasagiline with Anti-Depressants in Parkinson's Disease: A Retrospective Study
    Chhabria, Nisha
    Ghosh, Pritha
    Bahroo, Laxman
    Pagan, Fernando
    NEUROLOGY, 2011, 76 (09) : A485 - A486
  • [29] Identifying predictors of response to pramipexole treatment in early Parkinson's disease: A secondary analysis of the CALM-PD study
    Biglan, K. M.
    Brocht, A.
    McDermott, M. P.
    Kieburtz, K.
    MOVEMENT DISORDERS, 2007, 22 : S232 - S232
  • [30] Rasagiline for the treatment of gait disturbances in patients with Parkinson's disease (PD): an open label study
    Van Blercom, N.
    Linazasoro, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 338 - 338
12345